Trump says Iran war "close to over" amid hopes for more negotiations
Investing.com -- Coloplast (CSE:COLOB) announced Thursday the appointment of Gavin Wood as its next President and CEO, effective May 1, 2026.
The appointment concludes a year-long transition period following the departure of former CEO Kristian Villumsen in May 2025.
Wood will succeed interim CEO Lars Rasmussen, who has led the company through operational challenges and a strategy reset.
Wood brings two decades of medical technology leadership experience. Most recently, he served as Company Group Chairman of Johnson & Johnson MedTech EMEA, where he oversaw a multi-billion-dollar franchise spanning Surgery, Orthopedics, and Cardiovascular and Specialty Solutions.
His prior roles include Worldwide President of J&J’s Ethicon wound closure business and Executive Vice President Commercial at Mölnlycke. He currently serves as Vice Chair of the MedTech Europe trade association.
The Canadian executive, currently living in Switzerland, will relocate to Denmark before taking office.
Wood’s appointment brings senior medical technology leadership experience to Coloplast, including experience in wound care. His background includes running large organizations at a global scale.
Wood will take over as the company works to implement its Impact4 strategic plan unveiled in September.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.